NCT05718882终止不适用
Safety and Efficacy of Lenvatinib Combined With VIC-1911 in the Treatment of Lenvatinib-unresponsive or Lenvatinib-resistant Hepatocellular Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
This is a prospective clinical study aiming to test the safety and efficacy of lenvatinib in combination with Aurora kinase A inhibitor VIC-1911 in participate with lenvatinib-unresponsive or lenvatinib-resistant hepatocellular carcinoma(HCC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(1) Unlimited gender, aged 18-75 years; (2) Meets American Association for the Study of Liver Diseases (AASLD) or European Association for the Study of the Liver (EASL) clinical diagnostic criteria of hepatocellular carcinoma; (3) Barcelona Clinic Liver Cancer (BCLC) Stage C, and there is at least one measurable tumor in the liver (long diameter ≥ 1cm);(4) Lenvatinib unresponsive or lenvatinib resistant after standard treatment; (5) Child-Pugh A or scored 7 B; (6) Eastern Cooperative Oncology Group performance status score <= 1; (7) Platelet count >= 60x10^9/L, Prothrombin time prolonged <= 6 seconds.
排除标准
- •(1) Uncorrectable coagulopathy with obvious bleeding tendency; (2) Patients need long-term anticoagulant or anti platelet therapy and cannot stop the drugs; (3) Patients with unstable or active ulcer or gastrointestinal bleeding; (4) Heart disease requiring treatment or not well controlled high blood pressure; (5) Hepatic encephalopathy or refractory ascites requiring treatment; (6) There is a clear active infection; (7) Receiving radiotherapy/chemotherapy/interventional therapy for tumor within 4 weeks before the start of the study; (8) Severe insufficiency of important organs, such as severe cardiopulmonary insufficiency; (9) Other accompanying anti-tumor treatments; (10) The investigator assessed that the patient was unable or unwilling to comply with the protocol.
研究组 & 干预措施
Lenvatinib plus VIC-1911 combination therapy
Experimental
Subjects with lenvatinib unresponsive or lenvatinib resistant hepatocellular HCC will receive Lenvatinib plus VIC-1911 combination therapy.
干预措施: Lenvatinib Oral Product Plus VIC1911 (Drug)
结局指标
主要结局
Progression free survival
时间窗: 6 months after the last subject is enrolled.
Length of time from the start of combination therapy to progression of disease or death
次要结局
- Overall survival(6 months after the last subject is enrolled)
- Safety endpoint(6 months after the last subject is enrolled)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular CarcinomaMolecular Targeted TherapyHepatocellular CarcinomaNCT04642547RenJi Hospital30
进行中（未招募）
不适用
Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCCHepatocellular CarcinomaNCT06519721RenJi Hospital15
Unknown
1 期
Lenvatinib With Taxane Drugs Treatment for Advanced Gastric CancerHER2-negative Advanced Gastric CancerNCT05171530Ruijin Hospital19
已完成
1 期
Lenvatinib and Eribulin in Advanced Soft Tissue SarcomaSoft Tissue Sarcoma AdultAdvanced CancerLeiomyosarcomaLiposarcomaNCT03526679National Taiwan University Hospital30
已完成
1 期
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)Carcinoma, Renal CellNCT02454478Eisai Co., Ltd.7